IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study.

7041Background: Combining PD-1/ PD-L1 blockadewith hypomethylating agents(HMA) shows encouraging preliminary efficacy in AML, but immune features predictive of response are lacking. Methods: We tr...